Ritonavir-free oral 3C-like protease inhibition against COVID-19: a real-world verdict still waiting for its causal trial

The clinical management of mild-to-moderate Coronavirus disease 2019 (COVID-19) has transitioned from crisis-driven intervention to routine outpatient care, yet available therapeutic options remain insufficient to meet full clinical demand. Although Omicron-lineage infections are mostly mild and self-limiting, older adults, patients with multiple chronic illnesses and immunocompromised persons retain substantial risks of clinical deterioration, hospital admission and death (1,2). Oral early-phase antivirals therefore continue to serve important public-health functions, though two widely deployed agents carry notable practical drawbacks. Nirmatrelvir-ritonavir produces extensive, clinically relevant drug-drug interactions via ritonavir-mediated cytochrome P450 3A (CYP3A) inhibition, whereas molnupiravir delivers only modest clinical benefit alongside theoretical concerns over mutagenic potential (3-5). An oral single-agent main-protease inhibitor dispensing with pharmacokinetic boosting has long represented a desirable but unvalidated therapeutic objective (6). In this issue of the Journal of Thoracic Disease, Cheng and colleagues report a real-world assessment of leritrelvir based on a prospective, multicentre, open-label cohort of 1,527 adults with mild-to-moderate COVID-19 across 141 mainland Chinese sites, comparing early leritrelvir administration against standard care alone (7). Their findings merit careful, impartial appraisal; they do not constitute definitive clinical endorsement, but instead furnish a translational bridge between positive phase-3 placebo-controlled trial outcomes and the heterogeneous conditions of everyday clinical practice.

This cohort study enrolled 1,388 participants receiving oral leritrelvir (400 mg three-times-daily for five days) plus standard care and 139 participants managed by standard care only, during a period dominated by Omicron subvariants EG.5 and JN.1 (7). Investigators deployed three complementary analytical strategies: unadjusted analysis, multivariable regression adjustment and 1:1 propensity-score matching. Across these approaches, leritrelvir-treated participants achieved sustained symptom resolution approximately two days earlier and SARS-CoV-2 nucleic-acid negativity roughly one day earlier than control subjects. Effect directions remained consistent despite moderate magnitude variation across models, signalling sensitivity to baseline patient characteristics. No deaths or progression to severe COVID-19 occurred in either study arm, and adverse-event proportions were closely balanced within the matched cohort (approximately 19 % for each group) (7). These observational data reinforce prior randomised trial evidence. A multicentre double-blind placebo-controlled phase-3 trial of 1,359 adults previously demonstrated that unboosted leritrelvir shortened time to sustained clinical recovery, conferred statistically significant intergroup differences and augmented viral-load suppression by day four (8). By reproducing directionally consistent benefits within a far larger, more diverse real-world population spanning community and hospital settings, this cohort addresses an important evidence gap concerning performance of ritonavir-free 3C-like protease (3CLpro) inhibition when treatment allocation rests with clinical judgement rather than random assignment (7,8).

The SARS-CoV-2 3CLpro (also designated Mpro or nsp5) is a cysteine protease responsible for cleaving viral pp1a/pp1ab polyproteins into functional non-structural replication-associated proteins. High sequence conservation across coronaviruses and absence of human orthologues render it a therapeutically favourable target with a high genetic barrier to resistance (6,9). Outpatient antiviral care advanced markedly in late 2021 when EPIC-HR established that nirmatrelvir, a covalent peptidomimetic 3CLpro inhibitor, reduced COVID-19-related hospitalization and death by nearly 90% among high-risk unvaccinated outpatients (3). Nevertheless, nirmatrelvir cannot achieve adequate oral exposure without ritonavir-driven metabolic inhibition (3,10). This booster creates Paxlovid’s principal clinical limitation: CYP3A perturbation generates hazardous interactions with anticoagulants, antiarrhythmics, immunosuppressants, calcium-channel antagonists, statins and psychotropic medications, precisely the polypharmacy regimens common among high-risk candidates for antiviral therapy (10,11). International clinical guidance required extensive revision to incorporate drug-interaction checklists, and numerous eligible patients were consequently denied access to nirmatrelvir-ritonavir (10).

Chinese antiviral-drug development pursued two parallel pathways. Simnotrelvir retains ritonavir boosting; supported by positive phase-3 randomised data, it entered the domestic market in early 2023 as China’s first oral 3CLpro inhibitor (12). Leritrelvir (development code RAY1216), developed by Guangdong Raynovent Biotech, adopts an alternative chemical framework as an α-ketoamide peptidomimetic agent optimised for monotherapy use. Phase-1 work characterised its pharmacokinetic and safety profiles (13), while phase-2 randomised comparisons showed comparable viral-load reduction and shedding duration between unboosted leritrelvir and ritonavir-combined regimens, formally validating feasibility of booster-free administration (14). Subsequent phase-3 testing confirmed monotherapy efficacy, preceding conditional marketing authorisation in 2023 (8). Against this developmental backdrop, the present cohort represents the first large-scale real-world evaluation of ritonavir-sparing 3CLpro inhibition, addressing the most persistent clinical shortcoming of this drug class (7,8,13).

The study delivers three methodologically valuable contributions. First, its broad geographical recruitment captures a predominantly vaccinated, mildly symptomatic patient population during later Omicron waves, a context in which placebo-controlled outpatient antiviral trials have become ethically and logistically impracticable (7,8). Registry-based pragmatic observational research therefore assumes central importance for evaluating drug performance outside tightly constrained trial environments. Second, transparent multi-model reporting of crude, adjusted and propensity-score-matched outputs allows readers to assess residual confounding from measurable covariates including age, vaccination status, hospital admission and multiple chronic illnesses; the investigation adheres to STROBE reporting standards and sets a benchmark for high-quality observational analysis (7). Third, safety outcomes prove reassuring. Adverse-event frequencies were balanced following matching, and common toxicities including transaminase fluctuations, neutropenia, hyperuricaemia and mild gastrointestinal disturbance align with the expected benign profile of a virus-specific target absent from human biochemistry (6-8). For clinicians managing multimorbid older adults receiving complex concurrent medications, a ritonavir-free 3CLpro inhibitor with such tolerability carries tangible practical value.

Notwithstanding these strengths, observational design imposes clear interpretive boundaries, which the original authors appropriately acknowledge (7). Indication-based confounding constitutes the most substantial limitation. The approximate 10:1 imbalance between treated and control groups reflects non-random clinical prescribing; unmeasured variables such as baseline symptom severity, healthcare access or clinical practice patterns may independently modify recovery trajectories. Propensity-score matching balances only recorded covariates, and residual imbalances for cardiovascular disease, diabetes and hepatorenal disease persist even after matching (7). Additionally, the primary endpoint relies on participant-reported composite symptom assessment within an open-label framework, introducing reporting bias that may overestimate treatment-associated benefit. Incomplete follow-up represents a further caveat. A total of 320 participants failed to complete day-28 assessments; without individual dropout timelines, multiple imputation could not be performed, so informative censoring cannot be excluded (7). Violation of proportional-hazards assumptions means reported hazard ratios (HRs) reflect average event-rate summaries rather than constant treatment effects, requiring cautious clinical interpretation. Most critically, the study lacks statistical power for hard clinical endpoints. Zero recorded deaths or severe-disease transitions provide no evidence concerning hospitalisation, severe pneumonia or mortality, outcomes that define high-risk antiviral indications. The high-risk matched subgroup comprised merely 19 pairs and, although showing earlier symptom resolution (HR: 1.92, P=0.03), yielded a null viral-clearance difference (HR: 1.03, P=0.93); these exploratory analyses carry no multiplicity adjustment and generate hypotheses rather than confirm clinical efficacy (7). Observed reductions in symptom duration and nucleic-acid-testing positivity should therefore not be interpreted as proof of protection against serious clinical deterioration.

Biological and population-level reasoning contextualises these empirical observations. Virologically, early 3CLpro inhibition restricts formation of functional viral replication complexes, shortening intervals in which infectious virions and viral antigens drive innate immune activation and symptomatic illness (6,9). One-to-two-day gains in symptom resolution and nucleic-acid negativity correspond to moderate antiviral effects anticipated for early-initiated therapy within partially immune Omicron-era populations characterised by intrinsically rapid endogenous viral clearance. Phase-3 viral-load findings and current real-world time-to-negativity results reflect consistent mechanistic behaviour rather than conflicting evidence (7,8). Pharmacologically, elimination of ritonavir-mediated CYP3A inhibition constitutes leritrelvir’s key innovation, removing interaction-driven barriers that exclude polypharmacy patients from established 3CLpro-inhibitor treatment (10,11). For ageing multimorbid populations prioritised for early antiviral intervention, this is more than incremental convenience, but a determinant of treatment eligibility (3,10). Near-absent severe events also signal high background population immunity and enrolment bias towards largely vaccinated, mildly-affected participants. Marginal outpatient-antiviral benefit now concentrates within a shrinking high-risk subset rather than the general population (1,2,15).

Clinically, these real-world data support leritrelvir as a ritonavir-sparing alternative, particularly for patients with prohibitive drug-interaction risks, frailty or complex polypharmacy where nirmatrelvir-ritonavir cannot safely be deployed (7,10). Nevertheless, leritrelvir should not displace nirmatrelvir-ritonavir as standard-of-care on this evidence alone, given absence of head-to-head comparative efficacy and lack of hard-endpoint real-world data. Several research priorities emerge. Definitively establishing comparative effectiveness requires adequately powered randomised active-comparator trials, preferably against nirmatrelvir-ritonavir, enrolling high-risk and immunocompromised participants with hospitalisation and mortality as primary endpoints, settings where ritonavir-free formulations can expand real-world treatment access (3,7,16). Viral rebound, symptomatic recurrence and post-acute COVID-19 sequelae were not assessed in the present study. Since early antiviral exposure may modify long-COVID trajectories, extended prospective virological and symptomatic surveillance beyond day-28 deserves priority (17,18). Real-world registries should standardise collection of symptom-onset-to-treatment intervals, baseline viral loads and hard clinical outcomes to reduce reliance on surrogate symptom endpoints within observational research. Continuous resistance monitoring remains essential for all narrow-spectrum antivirals, especially among chronically infected immunocompromised hosts (9).

For guideline developers and public-health strategists, outpatient antiviral policy ought to weigh treatment accessibility and interaction burden alongside peak intrinsic efficacy. Securing actual drug delivery to eligible high-risk individuals, even with moderate average therapeutic gain, outweighs theoretical efficacy for agents rendered practically unusable by drug-interaction hazards (10,11). Ritonavir-free 3CLpro inhibitors widen the pool of treatable patients, an objective gaining relevance amid persistent post-acute pulmonary and long-COVID morbidity, conditions for which minimising acute viral exposure remains biologically plausible even following mild primary infection (18,19).

In summary, Cheng and co-workers present robust triangulated real-world evidence showing that early leritrelvir shortens symptomatic and virological recovery within routine outpatient practice. Observational effect directions align with preceding phase-3 randomised results and advance the clinical concept of booster-independent 3CLpro inhibition (7,8). These data document associations within an open-label cohort dominated by low-risk participants without severe clinical events. Definitive causal therapeutic recommendations, particularly claims of reduced hospitalisation or mortality, must await controlled trials powered for hard endpoints in high-risk populations.

Supplementary

The article’s supplementary files as

Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.